ValuEngine Upgrades Arcadia Biosciences (NASDAQ:RKDA) to Hold

Arcadia Biosciences (NASDAQ:RKDA) was upgraded by investment analysts at ValuEngine from a “sell” rating to a “hold” rating in a research note issued on Tuesday, ValuEngine reports.

Other analysts have also recently issued research reports about the stock. National Securities increased their price target on shares of Arcadia Biosciences from $12.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, August 15th. HC Wainwright reiterated a “buy” rating on shares of Arcadia Biosciences in a research note on Monday, August 12th.

Shares of RKDA stock opened at $4.88 on Tuesday. The company has a current ratio of 5.29, a quick ratio of 5.09 and a debt-to-equity ratio of 0.19. The company has a fifty day moving average price of $5.36 and a two-hundred day moving average price of $4.95. Arcadia Biosciences has a one year low of $1.82 and a one year high of $10.40.

Arcadia Biosciences (NASDAQ:RKDA) last announced its quarterly earnings results on Wednesday, August 14th. The basic materials company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.08). The firm had revenue of $0.20 million during the quarter, compared to analyst estimates of $0.20 million. Arcadia Biosciences had a negative net margin of 388.94% and a negative return on equity of 157.32%. On average, research analysts expect that Arcadia Biosciences will post -3.56 EPS for the current year.

In related news, Director Kevin Comcowich acquired 5,000 shares of the company’s stock in a transaction dated Tuesday, September 17th. The shares were bought at an average cost of $5.88 per share, with a total value of $29,400.00. Following the completion of the transaction, the director now directly owns 20,000 shares of the company’s stock, valued at $117,600. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CFO Matthew T. Plavan acquired 8,000 shares of the company’s stock in a transaction dated Wednesday, August 28th. The stock was bought at an average cost of $8.73 per share, for a total transaction of $69,840.00. The disclosure for this purchase can be found here. Insiders bought 33,200 shares of company stock worth $227,886 over the last three months. Insiders own 3.30% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of the company. Citadel Advisors LLC bought a new position in shares of Arcadia Biosciences in the second quarter valued at about $32,000. Cambridge Investment Research Advisors Inc. bought a new position in Arcadia Biosciences during the second quarter worth about $34,000. Vanguard Group Inc. increased its position in Arcadia Biosciences by 47.1% during the second quarter. Vanguard Group Inc. now owns 117,059 shares of the basic materials company’s stock worth $359,000 after acquiring an additional 37,472 shares during the period. Morgan Stanley increased its position in Arcadia Biosciences by 162,800.0% during the second quarter. Morgan Stanley now owns 81,450 shares of the basic materials company’s stock worth $250,000 after acquiring an additional 81,400 shares during the period. Finally, CVI Holdings LLC bought a new position in Arcadia Biosciences during the second quarter worth about $414,000. 6.58% of the stock is currently owned by institutional investors.

Arcadia Biosciences Company Profile

Arcadia Biosciences, Inc, an agricultural food ingredient company, develops and commercializes health and nutrition ingredient traits worldwide. The company offers a suite of agricultural productivity traits, including nitrogen use efficiency, water use efficiency and drought tolerance, salinity tolerance, and herbicide tolerance traits.

See Also: Beige Book

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.